|
Zilovertamab vedotin Clinical Trials
5 actively recruiting trials across 5 locations
Also known as: MK-2140, VLS-101
Pipeline
Phase 2: 2Phase 3: 1Phase 1/2: 1Phase 2/3: 1
Top Sponsors
- Merck Sharp & Dohme LLC5
Indications
- Cancer5
- Diffuse Large B-Cell Lymphoma3
- Lymphoma, Large B-Cell, Diffuse1
- Richter Transformation Lymphoma1
- Burkitt Lymphoma1
Mobile, Alabama1 trial
Anchorage, Alaska1 trial
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
Alaska Oncology and Hematology ( Site 0037)
Phase 2
Gilbert, Arizona1 trial
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Banner MD Anderson Cancer Center ( Site 0165)
Phase 3
Glendale, Arizona1 trial
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175)
Phase 2/3
Los Angeles, California1 trial
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Children's Hospital Los Angeles ( Site 1006)
Phase 1/2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.